taxonomy (1)
protein (3)
source (3)
structure (0)
composition (210)
disease (1)
reference (4)
site (62)
peptide (205)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) P0DTC2
- Recombinant Spike glycoprotein (FreeStyle 293-F) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) P0DTC2
- Recombinant Spike glycoprotein (HEK293) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) P0DTC2
Protein
Reported structure
- HexNAc:1 (avg mass : 221.2103 )
- HexNAc:1 dHex:1 (avg mass : 367.3533 )
- HexNAc:1 dHex:2 (avg mass : 513.4963 )
- HexNAc:2 (avg mass : 424.4053 )
- HexNAc:2 dHex:1 (avg mass : 570.5483 )
- HexNAc:2 dHex:2 (avg mass : 716.6913 )
- Hex:1 HexNAc:1 (avg mass : 383.3527 )
- Hex:1 HexNAc:1 NeuAc:2 (avg mass : 965.8685 )
- Hex:1 HexNAc:2 (avg mass : 586.5477 )
- Hex:1 HexNAc:2 dHex:1 (avg mass : 732.6907 )
- Hex:1 HexNAc:2 dHex:2 (avg mass : 878.8337 )
- Hex:2 HexNAc:2 (avg mass : 748.6901 )
- Hex:2 HexNAc:2 NeuAc:1 (avg mass : 1039.948 )
- Hex:2 HexNAc:2 NeuAc:2 (avg mass : 1331.2059 )
- Hex:2 HexNAc:2 dHex:1 (avg mass : 894.8331 )
- Hex:2 HexNAc:2 dHex:2 (avg mass : 1040.9761 )
- Hex:2 HexNAc:3 (avg mass : 951.8851 )
- Hex:2 HexNAc:3 dHex:1 (avg mass : 1098.0281 )
- Hex:2 HexNAc:3 dHex:2 (avg mass : 1244.1711 )
- Hex:2 HexNAc:5 (avg mass : 1358.2751 )
- Hex:3 HexNAc:2 (avg mass : 910.8325 )
- Hex:3 HexNAc:2 dHex:1 (avg mass : 1056.9755 )
- Hex:3 HexNAc:2 dHex:2 (avg mass : 1203.1185 )
- Hex:3 HexNAc:3 (avg mass : 1114.0275 )
- Hex:3 HexNAc:3 dHex:1 (avg mass : 1260.1705 )
- Hex:3 HexNAc:3 dHex:2 (avg mass : 1406.3135 )
- Hex:3 HexNAc:4 (avg mass : 1317.2225 )
- Hex:3 HexNAc:4 NeuAc:1 (avg mass : 1608.4804 )
- Hex:3 HexNAc:4 dHex:1 (avg mass : 1463.3655 )
- Hex:3 HexNAc:4 dHex:2 (avg mass : 1609.5085 )
- Hex:3 HexNAc:4 dHex:3 (avg mass : 1755.6515 )
- Hex:3 HexNAc:5 (avg mass : 1520.4175 )
- Hex:3 HexNAc:5 dHex:1 (avg mass : 1666.5605 )
- Hex:3 HexNAc:5 dHex:1 NeuAc:1 (avg mass : 1957.8184 )
- Hex:3 HexNAc:6 (avg mass : 1723.6125 )
- Hex:3 HexNAc:6 dHex:1 (avg mass : 1869.7555 )
- Hex:3 HexNAc:6 dHex:1 NeuAc:1 (avg mass : 2161.0134 )
- Hex:3 HexNAc:6 dHex:1 NeuAc:2 (avg mass : 2452.2713 )
- Hex:3 HexNAc:6 dHex:2 (avg mass : 2015.8985 )
- Hex:3 HexNAc:6 dHex:3 (avg mass : 2162.0415 )
- Hex:3 HexNAc:7 (avg mass : 1926.8075 )
- Hex:3 HexNAc:7 dHex:1 (avg mass : 2072.9505 )
- Hex:3 HexNAc:8 (avg mass : 2130.0025 )
- Hex:3 HexNAc:8 dHex:1 (avg mass : 2276.1455 )
- Hex:3 HexNAc:9 (avg mass : 2333.1975 )
- Hex:3 HexNAc:9 dHex:1 (avg mass : 2479.3405 )
- Hex:4 HexNAc:2 (avg mass : 1072.9749 )
- Hex:4 HexNAc:2 dHex:1 (avg mass : 1219.1179 )
- Hex:4 HexNAc:2 dHex:2 (avg mass : 1365.2609 )
- Hex:4 HexNAc:3 (avg mass : 1276.1699 )
- Hex:4 HexNAc:3 NeuAc:1 (avg mass : 1567.4278 )
- Hex:4 HexNAc:3 dHex:1 (avg mass : 1422.3129 )
- Hex:4 HexNAc:3 dHex:1 NeuAc:1 (avg mass : 1713.5708 )
- Hex:4 HexNAc:3 dHex:2 (avg mass : 1568.4559 )
- Hex:4 HexNAc:3 dHex:3 (avg mass : 1714.5989 )
- Hex:4 HexNAc:4 (avg mass : 1479.3649 )
- Hex:4 HexNAc:4 NeuAc:1 (avg mass : 1770.6228 )
- Hex:4 HexNAc:4 dHex:1 (avg mass : 1625.5079 )
- Hex:4 HexNAc:4 dHex:1 NeuAc:1 (avg mass : 1916.7658 )
- Hex:4 HexNAc:4 dHex:2 (avg mass : 1771.6509 )
- Hex:4 HexNAc:5 (avg mass : 1682.5599 )
- Hex:4 HexNAc:5 NeuAc:1 (avg mass : 1973.8178 )
- Hex:4 HexNAc:5 NeuAc:2 (avg mass : 2265.0757 )
- Hex:4 HexNAc:5 dHex:1 (avg mass : 1828.7029 )
- Hex:4 HexNAc:5 dHex:1 NeuAc:1 (avg mass : 2119.9608 )
- Hex:4 HexNAc:5 dHex:1 NeuAc:2 (avg mass : 2411.2187 )
- Hex:4 HexNAc:5 dHex:2 (avg mass : 1974.8459 )
- Hex:4 HexNAc:5 dHex:2 NeuAc:1 (avg mass : 2266.1038 )
- Hex:4 HexNAc:6 (avg mass : 1885.7549 )
- Hex:4 HexNAc:6 NeuAc:1 (avg mass : 2177.0128 )
- Hex:4 HexNAc:6 dHex:1 (avg mass : 2031.8979 )
- Hex:4 HexNAc:6 dHex:2 (avg mass : 2178.0409 )
- Hex:4 HexNAc:6 dHex:4 (avg mass : 2470.3269 )
- Hex:4 HexNAc:7 (avg mass : 2088.9499 )
- Hex:4 HexNAc:7 dHex:1 (avg mass : 2235.0929 )
- Hex:4 HexNAc:7 dHex:2 (avg mass : 2381.2359 )
- Hex:4 HexNAc:7 dHex:3 (avg mass : 2527.3789 )
- Hex:4 HexNAc:8 (avg mass : 2292.1449 )
- Hex:4 HexNAc:9 (avg mass : 2495.3399 )
- Hex:4 HexNAc:9 dHex:1 (avg mass : 2641.4829 )
- Hex:5 HexNAc:2 (avg mass : 1235.1173 )
- Hex:5 HexNAc:2 dHex:1 (avg mass : 1381.2603 )
- Hex:5 HexNAc:2 dHex:2 (avg mass : 1527.4033 )
- Hex:5 HexNAc:3 (avg mass : 1438.3123 )
- Hex:5 HexNAc:3 NeuAc:1 (avg mass : 1729.5702 )
- Hex:5 HexNAc:3 dHex:1 (avg mass : 1584.4553 )
- Hex:5 HexNAc:3 dHex:2 (avg mass : 1730.5983 )
- Hex:5 HexNAc:4 (avg mass : 1641.5073 )
- Hex:5 HexNAc:4 NeuAc:1 (avg mass : 1932.7652 )
- Hex:5 HexNAc:4 NeuAc:2 (avg mass : 2224.0231 )
- Hex:5 HexNAc:4 dHex:1 (avg mass : 1787.6503 )
- Hex:5 HexNAc:4 dHex:1 NeuAc:1 (avg mass : 2078.9082 )
- Hex:5 HexNAc:4 dHex:1 NeuAc:2 (avg mass : 2370.1661 )
- Hex:5 HexNAc:4 dHex:2 (avg mass : 1933.7933 )
- Hex:5 HexNAc:4 dHex:2 NeuAc:1 (avg mass : 2225.0512 )
- Hex:5 HexNAc:4 dHex:3 (avg mass : 2079.9363 )
- Hex:5 HexNAc:4 dHex:3 NeuAc:1 (avg mass : 2371.1942 )
- Hex:5 HexNAc:4 dHex:4 (avg mass : 2226.0793 )
- Hex:5 HexNAc:4 dHex:5 (avg mass : 2372.2223 )
- Hex:5 HexNAc:5 (avg mass : 1844.7023 )
- Hex:5 HexNAc:5 NeuAc:1 (avg mass : 2135.9602 )
- Hex:5 HexNAc:5 NeuAc:2 (avg mass : 2427.2181 )
- Hex:5 HexNAc:5 dHex:1 (avg mass : 1990.8453 )
- Hex:5 HexNAc:5 dHex:1 NeuAc:1 (avg mass : 2282.1032 )
- Hex:5 HexNAc:5 dHex:1 NeuAc:2 (avg mass : 2573.3611 )
- Hex:5 HexNAc:5 dHex:2 (avg mass : 2136.9883 )
- Hex:5 HexNAc:5 dHex:3 (avg mass : 2283.1313 )
- Hex:5 HexNAc:6 (avg mass : 2047.8973 )
- Hex:5 HexNAc:6 dHex:1 (avg mass : 2194.0403 )
- Hex:5 HexNAc:6 dHex:1 NeuAc:1 (avg mass : 2485.2982 )
- Hex:5 HexNAc:6 dHex:1 NeuAc:2 (avg mass : 2776.5561 )
- Hex:5 HexNAc:6 dHex:1 NeuAc:3 (avg mass : 3067.814 )
- Hex:5 HexNAc:6 dHex:2 (avg mass : 2340.1833 )
- Hex:5 HexNAc:8 dHex:1 (avg mass : 2600.4303 )
- Hex:6 HexNAc:2 (avg mass : 1397.2597 )
- Hex:6 HexNAc:3 (avg mass : 1600.4547 )
- Hex:6 HexNAc:3 NeuAc:1 (avg mass : 1891.7126 )
- Hex:6 HexNAc:3 dHex:1 (avg mass : 1746.5977 )
- Hex:6 HexNAc:3 dHex:1 NeuAc:1 (avg mass : 2037.8556 )
- Hex:6 HexNAc:4 (avg mass : 1803.6497 )
- Hex:6 HexNAc:4 NeuAc:1 (avg mass : 2094.9076 )
- Hex:6 HexNAc:4 dHex:1 (avg mass : 1949.7927 )
- Hex:6 HexNAc:4 dHex:1 NeuAc:1 (avg mass : 2241.0506 )
- Hex:6 HexNAc:4 dHex:2 (avg mass : 2095.9357 )
- Hex:6 HexNAc:4 dHex:3 (avg mass : 2242.0787 )
- Hex:6 HexNAc:5 (avg mass : 2006.8447 )
- Hex:6 HexNAc:5 NeuAc:1 (avg mass : 2298.1026 )
- Hex:6 HexNAc:5 NeuAc:2 (avg mass : 2589.3605 )
- Hex:6 HexNAc:5 NeuAc:3 (avg mass : 2880.6184 )
- Hex:6 HexNAc:5 dHex:1 (avg mass : 2152.9877 )
- Hex:6 HexNAc:5 dHex:1 NeuAc:1 (avg mass : 2444.2456 )
- Hex:6 HexNAc:5 dHex:1 NeuAc:2 (avg mass : 2735.5035 )
- Hex:6 HexNAc:5 dHex:1 NeuAc:3 (avg mass : 3026.7614 )
- Hex:6 HexNAc:5 dHex:2 (avg mass : 2299.1307 )
- Hex:6 HexNAc:5 dHex:2 NeuAc:1 (avg mass : 2590.3886 )
- Hex:6 HexNAc:5 dHex:3 NeuAc:1 (avg mass : 2736.5316 )
- Hex:6 HexNAc:6 (avg mass : 2210.0397 )
- Hex:6 HexNAc:6 NeuAc:1 (avg mass : 2501.2976 )
- Hex:6 HexNAc:6 NeuAc:2 (avg mass : 2792.5555 )
- Hex:6 HexNAc:6 dHex:1 (avg mass : 2356.1827 )
- Hex:6 HexNAc:6 dHex:1 NeuAc:1 (avg mass : 2647.4406 )
- Hex:6 HexNAc:6 dHex:1 NeuAc:2 (avg mass : 2938.6985 )
- Hex:6 HexNAc:6 dHex:1 NeuAc:3 (avg mass : 3229.9564 )
- Hex:6 HexNAc:6 dHex:2 (avg mass : 2502.3257 )
- Hex:6 HexNAc:6 dHex:3 (avg mass : 2648.4687 )
- Hex:6 HexNAc:7 (avg mass : 2413.2347 )
- Hex:6 HexNAc:7 dHex:1 (avg mass : 2559.3777 )
- Hex:6 HexNAc:7 dHex:1 NeuAc:4 (avg mass : 3724.4093 )
- Hex:6 HexNAc:8 (avg mass : 2616.4297 )
- Hex:6 HexNAc:9 (avg mass : 2819.6247 )
- Hex:7 HexNAc:2 (avg mass : 1559.4021 )
- Hex:7 HexNAc:3 (avg mass : 1762.5971 )
- Hex:7 HexNAc:4 (avg mass : 1965.7921 )
- Hex:7 HexNAc:4 NeuAc:1 (avg mass : 2257.05 )
- Hex:7 HexNAc:4 dHex:1 (avg mass : 2111.9351 )
- Hex:7 HexNAc:4 dHex:3 (avg mass : 2404.2211 )
- Hex:7 HexNAc:5 (avg mass : 2168.9871 )
- Hex:7 HexNAc:5 dHex:1 (avg mass : 2315.1301 )
- Hex:7 HexNAc:5 dHex:1 NeuAc:1 (avg mass : 2606.388 )
- Hex:7 HexNAc:5 dHex:1 NeuAc:2 (avg mass : 2897.6459 )
- Hex:7 HexNAc:5 dHex:2 (avg mass : 2461.2731 )
- Hex:7 HexNAc:6 (avg mass : 2372.1821 )
- Hex:7 HexNAc:6 NeuAc:1 (avg mass : 2663.44 )
- Hex:7 HexNAc:6 NeuAc:2 (avg mass : 2954.6979 )
- Hex:7 HexNAc:6 NeuAc:3 (avg mass : 3245.9558 )
- Hex:7 HexNAc:6 NeuAc:4 (avg mass : 3537.2137 )
- Hex:7 HexNAc:6 dHex:1 (avg mass : 2518.3251 )
- Hex:7 HexNAc:6 dHex:1 NeuAc:1 (avg mass : 2809.583 )
- Hex:7 HexNAc:6 dHex:1 NeuAc:2 (avg mass : 3100.8409 )
- Hex:7 HexNAc:6 dHex:1 NeuAc:3 (avg mass : 3392.0988 )
- Hex:7 HexNAc:6 dHex:1 NeuAc:4 (avg mass : 3683.3567 )
- Hex:7 HexNAc:6 dHex:4 NeuAc:1 (avg mass : 3248.012 )
- Hex:7 HexNAc:6 dHex:4 NeuAc:2 (avg mass : 3539.2699 )
- Hex:7 HexNAc:6 dHex:5 NeuAc:4 (avg mass : 4267.9287 )
- Hex:7 HexNAc:7 dHex:1 (avg mass : 2721.5201 )
- Hex:7 HexNAc:7 dHex:1 NeuAc:2 (avg mass : 3304.0359 )
- Hex:7 HexNAc:7 dHex:1 NeuAc:3 (avg mass : 3595.2938 )
- Hex:7 HexNAc:7 dHex:1 NeuAc:4 (avg mass : 3886.5517 )
- Hex:7 HexNAc:7 dHex:3 (avg mass : 3013.8061 )
- Hex:7 HexNAc:8 (avg mass : 2778.5721 )
- Hex:8 HexNAc:2 (avg mass : 1721.5445 )
- Hex:8 HexNAc:5 (avg mass : 2331.1295 )
- Hex:8 HexNAc:6 (avg mass : 2534.3245 )
- Hex:8 HexNAc:6 NeuAc:1 (avg mass : 2825.5824 )
- Hex:8 HexNAc:6 dHex:1 NeuAc:1 (avg mass : 2971.7254 )
- Hex:8 HexNAc:7 (avg mass : 2737.5195 )
- Hex:8 HexNAc:7 NeuAc:1 (avg mass : 3028.7774 )
- Hex:8 HexNAc:7 dHex:1 (avg mass : 2883.6625 )
- Hex:8 HexNAc:7 dHex:1 NeuAc:1 (avg mass : 3174.9204 )
- Hex:8 HexNAc:7 dHex:1 NeuAc:2 (avg mass : 3466.1783 )
- Hex:8 HexNAc:7 dHex:1 NeuAc:3 (avg mass : 3757.4362 )
- Hex:8 HexNAc:7 dHex:1 NeuAc:4 (avg mass : 4048.6941 )
- Hex:8 HexNAc:8 (avg mass : 2940.7145 )
- Hex:8 HexNAc:8 dHex:1 (avg mass : 3086.8575 )
- Hex:9 HexNAc:2 (avg mass : 1883.6869 )
- Hex:9 HexNAc:4 dHex:1 (avg mass : 2436.2199 )
- Hex:9 HexNAc:5 dHex:1 (avg mass : 2639.4149 )
- Hex:9 HexNAc:6 (avg mass : 2696.4669 )
- Hex:9 HexNAc:6 dHex:1 NeuAc:2 (avg mass : 3425.1257 )
- Hex:9 HexNAc:8 (avg mass : 3102.8569 )
- Hex:9 HexNAc:8 dHex:1 (avg mass : 3248.9999 )
- Hex:9 HexNAc:8 dHex:1 NeuAc:3 (avg mass : 4122.7736 )
- Hex:9 HexNAc:8 dHex:1 NeuAc:4 (avg mass : 4414.0315 )
- Hex:9 HexNAc:9 dHex:1 (avg mass : 3452.1949 )
- Hex:10 HexNAc:2 (avg mass : 2045.8293 )
- Hex:10 HexNAc:6 dHex:1 NeuAc:1 (avg mass : 3296.0102 )
- Hex:10 HexNAc:9 (avg mass : 3468.1943 )
- Hex:10 HexNAc:9 dHex:1 (avg mass : 3614.3373 )
- Hex:11 HexNAc:2 (avg mass : 2207.9717 )
- Hex:11 HexNAc:6 dHex:1 (avg mass : 3166.8947 )
Composition
- COVID-19 (DOID:0080600)
Disease
- Deducing the N- and O- glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2 (2020 - Asif Shajahan, Nitin T. Supekar, Anne S. Gleinich, Parastoo Azadi) / Status : Reviewed
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Site-specific glycan analysis of the SARS-CoV-2 spike (2020 - Yasunori Watanabe, Joel D. Allen, Daniel Wrapp, Jason S. McLellan, Max Crispin) / Status : Unreviewed
Reference
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- Recombinant Spike glycoprotein (FreeStyle 293-F) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- Recombinant Spike glycoprotein (HEK293) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
Reported glycosite
- QCVNLTTR (8aa)
- SNVTWF (6aa)
- FSNVTWF (7aa)
- FSNVTWF (7aa)
- FSNVTWF (7aa)
- FSNVTW (6aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- FHAIHVSGTNGTK (13aa)
- FHAIHVSGTNGTKR (14aa)
- HAIHVSGTNGTKR (13aa)
- HAIHVSGTNGTKRF (14aa)
- HAIHVSGTNGTKRF (14aa)
- HAIHVSGTNGTKRFDNPVLPF (21aa)
- FHAIHVSGTNGTKRF (15aa)
- HAIHVSGTNGTK (12aa)
- SLLIVNNATNVVIK (14aa)
- IVNNATNVVIKVCEF (15aa)
- IVNNATNVVIKVCEF (15aa)
- LIVNNATNVVIK (12aa)
- LIVNNATNVVIK (12aa)
- SNIIRGWIFGTTLDSKTQSLLIVNNATNVVIK (32aa)
- TQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHK (34aa)
- IVNNATNVVIK (11aa)
- IVNNATNVVIK (11aa)
- LIVNNATNVVIKVCEF (16aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- GWIFGTTLDSKTQSLLIVNNATNVVIK (27aa)
- TQSLLIVNNATNVVIKVCE (19aa)
- HKNNK (5aa)
- YHKNNKSWMESEF (13aa)
- FQFCNDPFLGVYYHKNNKSWMESE (24aa)
- FQFCNDPFLGVYYHKNNK (18aa)
- FQFCNDPFLGVYYHKNNK (18aa)
- VCEFQFCNDPFLGVYYHKNNK (21aa)
- FQFCNDPFLGVYYHKNNKSWMESEF (25aa)
- VCEFQFCNDPFLGVYYHKNNKSWMESEFR (29aa)
- VCEFQFCNDPFLGVYYHKNNKSWMESEFR (29aa)
- FQFCNDPFLGVYYHKNNKSWME (22aa)
- NNKSWMESEFR (11aa)
- VYSSANNCTFEY (12aa)
- SSANNCTFEYVSQPF (15aa)
- SSANNCTF (8aa)
- SSANNCTF (8aa)
- SSANNCTFEY (10aa)
- SSANNCTFEY (10aa)
- VYSSANNCTFEYVSQPFLMDLEGK (24aa)
- VYSSANNCTFEYVSQPFLMDLEGK (24aa)
- SEFRVYSSANNCTFEYVSQPFLMDLE (26aa)
- VYSSANNCTFE (11aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- FRVYSSANNCTFE (13aa)
- VYSSANNCTFEYVSQPFLMDLEGKQGNFKNLR (32aa)
- VYSSANNCTF (10aa)
- SALEPLVDLPIGINITRFQTL (21aa)
- VDLPIGINITR (11aa)
- SALEPLVDLPIGINITRFQTLL (22aa)
- SALEPLVDLPIGINITRF (18aa)
- GINIT (5aa)
- PLVDLPIGINITR (13aa)
- PLVDLPIGINITR (13aa)
- SALEPLVDLPIGINITR (17aa)
- DLPQGFSALEPLVDLPIGINITR (23aa)
- KYNENGTIT (9aa)
- FLLKYNENGTIT (12aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- TFLLKYNENGTITDAVDCALDPLSETK (27aa)
- NGTITDAVDCALDPLSETK (19aa)
- NGTITDAVDCALDPLSETK (19aa)
- NGTITDAVDCALDPLSETKCTLK (23aa)
- TFLLKYNENGTITDAVDCALDPLSE (25aa)
- NGTITDAVDCALDPLSEK (18aa)
- NGTITDAVDCALDPLSE (17aa)
- NGTITDAVDCALDPLSE (17aa)
- VQPTESIVR (9aa)
- VQPTESIVR (9aa)
- FPNITNLCPF (10aa)
- RVQPTESIVRFPNITNLCPFGEVF (24aa)
- VQPTESIVRFPNITN (15aa)
- FPNITNL (7aa)
- RVQPTESIVRFPNITNLCPF (20aa)
- RFPNIT (6aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- FPNITNLCPFGEVFNATRFASVYAWNR (27aa)
- FPNITNLCPFGEVFNATRFASVYAWNR (27aa)
- KGIYQTSNFRVQPTESIVRFPNITNLCPFGE (31aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- SIVRFPNITNLCPFGE (16aa)
- FPNITNLCPFGE (12aa)
- FPNITNLCPFGE (12aa)
- GEVFNATRF (9aa)
- GEVFNATRF (9aa)
- GEVFNATRF (9aa)
- GEVFNATR (8aa)
- GEVFNATR (8aa)
- VFNATR (6aa)
- NATRF (5aa)
- CPFGEVFNATR (11aa)
- GGVSVITPGTNTSNQVAVL (19aa)
- GGVSVITPGTNTSNQVAVLY (20aa)
- GGVSVITPGTNTSNQVAVLY (20aa)
- VITPGTNTS (9aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- DPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (57aa)
- DPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (57aa)
- DPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (57aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- YQDVNCTEVPVAIHADQL (18aa)
- QDVNCTEVPVAIHADQL (17aa)
- LYQDVNCT (8aa)
- AGCLIGAEHVNNSY (14aa)
- NNSYECDIPI (10aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- AGCLIGAEHVNNSYE (15aa)
- AGCLIGAEHVNNSYE (15aa)
- VYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (48aa)
- HVNNSYECDIPIGAGICASYQTQTNSPR (28aa)
- HVNNSYECDIPIGAGICASYQTQTNSPR (28aa)
- HVNNSYE (7aa)
- HVNNSYE (7aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSP (35aa)
- IIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEIL (36aa)
- YSNNSIAIPT (10aa)
- YSNNSIA (7aa)
- SIIAYTMSLGAENSVAYSN (19aa)
- SNNSIAIPT (9aa)
- AYSNNSIAIPTNFTISVTTEILPVSMTK (28aa)
- SIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTK (43aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- IIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSN (60aa)
- IIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMT (41aa)
- IIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMT (41aa)
- SNNSIAIPTNF (11aa)
- SNNSIAIPTNF (11aa)
- SIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTEC (59aa)
- IIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSM (40aa)
- IIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIA (80aa)
- TNFTISVTTEILPVSMTK (18aa)
- NSIAIPTNFTISVTTEILPVSMTK (24aa)
- SIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGS (68aa)
- SNNSIAIPTNFTISVTTEILPVSMTK (26aa)
- NFTIS (5aa)
- IIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQL (72aa)
- NFTISVTTEILPVSMTK (17aa)
- IPTNFTISVTTEILPVSMTK (20aa)
- DFGGFNF (7aa)
- NFSQILPDPSK (11aa)
- NFNFSQILPDPSKPSKR (17aa)
- NFSQILPDPSKPSK (14aa)
- NFSQILPDPSKPS (13aa)
- FGGFNFS (7aa)
- DFGGFNFSQILPDPSK (16aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- QIYKTPPIKDFGGFNFSQILPDPSKPSK (28aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- NFSQILPDPSKPSKR (15aa)
- VPAQEKNFTTAPA (13aa)
- VPAQEKNF (8aa)
- VPAQEKNF (8aa)
- VPAQEKNF (8aa)
- VTYVPAQEKNFTTAPAICHDGK (22aa)
- NFTTAP (6aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG (40aa)
- PAQEKNFTTAPAICHDGKAHFPR (23aa)
- VVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (32aa)
- VPAQEKNFTTAPAICH (16aa)
- HVTYVPAQEKNF (12aa)
- VPAQEKNFTTAPAICHDGKAHFPREGVF (28aa)
- NFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQ (33aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- KNFTTAPAICHDGK (14aa)
- KNFTTAPAICHDGK (14aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- CVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPRE (61aa)
- AHFPREGVFVSNGTHWFVTQR (21aa)
- AHFPREGVFVSNGTHWFVTQR (21aa)
- KNFTTAPAICHDGKAHFPRE (20aa)
- NFTTAPAICHDGKAHFPR (18aa)
- NFTTAPAICHDGKAHFPR (18aa)
- NFTTAPAICHDGKA (14aa)
- NFTTAPAICHDGK (13aa)
- NFTTAPAICHDGK (13aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- AHFPREGVFVSNGTHWFVT (19aa)
- AHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPL (55aa)
- AHFPREGVFVSNGTHW (16aa)
- EGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPL (50aa)
- AHFPREGVFVSNGT (14aa)
- VSNGTHW (7aa)
- VSNGTHWF (8aa)
- EGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPE (53aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- EGVFVSNGTHWF (12aa)
- EGVFVSNGTHWFVTQRNFYEPQIITT (26aa)
- AHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVS (37aa)
- EGVFVSN (7aa)
- NGTHWFV (7aa)
- NGTHWFVT (8aa)
- GVFVSNGTHWFVTQR (15aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHWFVTQRN (17aa)
- AHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDP (54aa)
- VSNGTHWFVTQR (12aa)
- EGVFVSNGTHWFVTQRNFYEPQIITTDN (28aa)
- IGIVNNT (7aa)
- IVNNT (5aa)
- KNH (3aa)
- KYFKNHTS (8aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- YFKNHTSPDVDLGDISGINASVVNIQKE (28aa)
- YFKNHTSPDVDLGDISGINASVVNIQKE (28aa)
- KNHTSPDVDLGDISGINASVVNIQK (25aa)
- GINASVV (7aa)
- GINAS (5aa)
- NHTSPDVDLGDISGINASVVNIQKEIDR (28aa)
- KNLNE (5aa)
- KNLNES (6aa)
- KNLN (4aa)
- EIDRLNEVAKNLNESLIDLQELGK (24aa)
- LNEVAKNLNESLIDLQELGK (20aa)
- NLNESLIDLQELGK (14aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- IDRLNEVAKNLNESLIDLQE (20aa)
- IDRLNEVAKNLNE (13aa)
- LNEVAKNLNESLIDLQELGKYEQYIK (26aa)
- NLNESLIDLQELGKYEQYIK (20aa)
- NLNESLIDLQELGKYEQYIK (20aa)
- NLNESLIDLQE (11aa)
- VAKNLNESLIDLQE (14aa)
Mass spectrometry observed peptide
-
- HexNAc:1 / N-Linked (avg mass : 221.2103)
- BTI-Tn-5B1-4 (CVCL_C190)
- HEK293 (CVCL_0045)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- Recombinant Spike glycoprotein (HEK293) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPFGE (12aa)
- FPNITNLCPFGE (12aa)
- FPNITNLCPFGEVFNATRFASVYAWNR (27aa)
- FPNITNLCPFGEVFNATRFASVYAWNR (27aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNFSQILPDPSK (16aa)
- KNFTTAPAICHDGK (14aa)
- KNFTTAPAICHDGK (14aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- NFTTAPAICHDGK (13aa)
- NFTTAPAICHDGK (13aa)
- GVFVSNGTHWFVTQR (15aa)
- GVFVSNGTHWFVTQR (15aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- VAKNLNESLIDLQE (14aa)
-
- HexNAc:1 dHex:1 / N-Linked (avg mass : 367.3533)
- BTI-Tn-5B1-4 (CVCL_C190)
- HEK293 (CVCL_0045)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- Recombinant Spike glycoprotein (HEK293) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPFGE (12aa)
- FPNITNLCPFGE (12aa)
- AGCLIGAEHVNNSYE (15aa)
- AGCLIGAEHVNNSYE (15aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- KNFTTAPAICHDGK (14aa)
- KNFTTAPAICHDGK (14aa)
- NFTTAPAICHDGK (13aa)
- NFTTAPAICHDGK (13aa)
- GVFVSNGTHWFVTQR (15aa)
- GVFVSNGTHWFVTQR (15aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- VAKNLNESLIDLQE (14aa)
-
- HexNAc:2 / N-Linked (avg mass : 424.4053)
- BTI-Tn-5B1-4 (CVCL_C190)
- HEK293 (CVCL_0045)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- Recombinant Spike glycoprotein (HEK293) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- NGTITDAVDCALDPLSE (17aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- KNFTTAPAICHDGK (14aa)
- KNFTTAPAICHDGK (14aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- NFTTAPAICHDGK (13aa)
- NFTTAPAICHDGK (13aa)
- GVFVSNGTHWFVTQR (15aa)
- GVFVSNGTHWFVTQR (15aa)
- VAKNLNESLIDLQE (14aa)
-
- HexNAc:1 dHex:2 / N-Linked (avg mass : 513.4963)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- AGCLIGAEHVNNSYE (15aa)
- AGCLIGAEHVNNSYE (15aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- KNFTTAPAICHDGK (14aa)
- KNFTTAPAICHDGK (14aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NLNESLIDLQELGK (14aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNESLIDLQE (14aa)
-
- HexNAc:2 dHex:1 / N-Linked (avg mass : 570.5483)
- BTI-Tn-5B1-4 (CVCL_C190)
- HEK293 (CVCL_0045)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- Recombinant Spike glycoprotein (HEK293) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- VYSSANNCTFE (11aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- NGTITDAVDCALDPLSE (17aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- AGCLIGAEHVNNSYE (15aa)
- AGCLIGAEHVNNSYE (15aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:1 HexNAc:2 / N-Linked (avg mass : 586.5477)
- BTI-Tn-5B1-4 (CVCL_C190)
- HEK293 (CVCL_0045)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- Recombinant Spike glycoprotein (HEK293) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- VYSSANNCTFE (11aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- KNFTTAPAICHDGK (14aa)
- KNFTTAPAICHDGK (14aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- NFTTAPAICHDGK (13aa)
- NFTTAPAICHDGK (13aa)
- EGVFVSNGTHW (11aa)
- GVFVSNGTHWFVTQR (15aa)
- GVFVSNGTHWFVTQR (15aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- VAKNLNESLIDLQE (14aa)
-
- HexNAc:2 dHex:2 / N-Linked (avg mass : 716.6913)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SEFRVYSSANNCTFE (15aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- AGCLIGAEHVNNSYE (15aa)
- AGCLIGAEHVNNSYE (15aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:1 HexNAc:2 dHex:1 / N-Linked (avg mass : 732.6907)
- BTI-Tn-5B1-4 (CVCL_C190)
- HEK293 (CVCL_0045)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- Recombinant Spike glycoprotein (HEK293) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- NGTITDAVDCALDPLSE (17aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- GIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR (36aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GVFVSNGTHWFVTQR (15aa)
- GVFVSNGTHWFVTQR (15aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:2 HexNAc:2 / N-Linked (avg mass : 748.6901)
- BTI-Tn-5B1-4 (CVCL_C190)
- HEK293 (CVCL_0045)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- Recombinant Spike glycoprotein (HEK293) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- HAIHVSGTNGTK (12aa)
- LIVNNATNVVIK (12aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- VYSSANNCTFE (11aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- NGTITDAVDCALDPLSE (17aa)
- FPNITNLCPFGE (12aa)
- FPNITNLCPFGE (12aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- GEVFNATR (8aa)
- GEVFNATR (8aa)
- CPFGEVFNATR (11aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNFSQILPDPSK (16aa)
- NFSQILPDPSK (11aa)
- KNFTTAPAICHDGK (14aa)
- KNFTTAPAICHDGK (14aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- VPAQEKNF (8aa)
- VPAQEKNF (8aa)
- VPAQEKNF (8aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- NFTTAPAICHDGK (13aa)
- NFTTAPAICHDGK (13aa)
- GVFVSNGTHWFVTQR (15aa)
- GVFVSNGTHWFVTQR (15aa)
- VSNGTHWF (8aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- EGVFVSNGTHWF (12aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:1 HexNAc:2 dHex:2 / N-Linked (avg mass : 878.8337)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- VYSSANNCTFE (11aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- KNFTTAPAICHDGK (14aa)
- KNFTTAPAICHDGK (14aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- YFKNHTSPDVDLGDISGINASVVNIQKE (28aa)
- YFKNHTSPDVDLGDISGINASVVNIQKE (28aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:2 HexNAc:2 dHex:1 / N-Linked (avg mass : 894.8331)
- BTI-Tn-5B1-4 (CVCL_C190)
- HEK293 (CVCL_0045)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- Recombinant Spike glycoprotein (HEK293) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- FSNVTWF (7aa)
- FSNVTWF (7aa)
- FSNVTWF (7aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SNVTWF (6aa)
- FHAIHVSGTNGTK (13aa)
- HAIHVSGTNGTK (12aa)
- FHAIHVSGTNGTKR (14aa)
- HAIHVSGTNGTKR (13aa)
- LIVNNATNVVIK (12aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- FQFCNDPFLGVYYHKNNK (18aa)
- FQFCNDPFLGVYYHKNNK (18aa)
- VYSSANNCTFE (11aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- SSANNCTF (8aa)
- SSANNCTF (8aa)
- NGTITDAVDCALDPLSE (17aa)
- NGTITDAVDCALDPLSE (17aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPF (10aa)
- SIVRFPNITNLCPFGE (16aa)
- FPNITNLCPFGE (12aa)
- FPNITNLCPFGE (12aa)
- FPNITNL (7aa)
- VFNATR (6aa)
- GEVFNATR (8aa)
- GEVFNATR (8aa)
- CPFGEVFNATR (11aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- AGCLIGAEHVNNSYE (15aa)
- AGCLIGAEHVNNSYE (15aa)
- HVNNSYECDIPIGAGICASYQTQTNSPR (28aa)
- HVNNSYECDIPIGAGICASYQTQTNSPR (28aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- NFSQILPDPSK (11aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSK (16aa)
- KNFTTAPAICHDGK (14aa)
- KNFTTAPAICHDGK (14aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- VPAQEKNF (8aa)
- VPAQEKNF (8aa)
- VPAQEKNF (8aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- NFTTAPAICHDGK (13aa)
- NFTTAPAICHDGK (13aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- HVTYVPAQEKNF (12aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GVFVSNGTHWFVTQR (15aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- EGVFVSNGTHWF (12aa)
- VSNGTHW (7aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NLNESLIDLQELGK (14aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:3 HexNAc:2 / N-Linked (avg mass : 910.8325)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Site-specific glycan analysis of the SARS-CoV-2 spike (2020 - Yasunori Watanabe, Joel D. Allen, Daniel Wrapp, Jason S. McLellan, Max Crispin) / Status : Unreviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- Recombinant Spike glycoprotein (FreeStyle 293-F) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- Recombinant Spike glycoprotein (HEK293) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- FSNVTWF (7aa)
- FSNVTWF (7aa)
- FSNVTWF (7aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- FSNVTW (6aa)
- SNVTWF (6aa)
- HAIHVSGTNGTK (12aa)
- FHAIHVSGTNGTKR (14aa)
- FHAIHVSGTNGTKRF (15aa)
- LIVNNATNVVIK (12aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- SEFRVYSSANNCTFEYVSQPFLMDLE (26aa)
- VYSSANNCTFE (11aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- SSANNCTF (8aa)
- SSANNCTF (8aa)
- VYSSANNCTF (10aa)
- NGTITDAVDCALDPLSE (17aa)
- NGTITDAVDCALDPLSE (17aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- TFLLKYNENGTITDAVDCALDPLSETK (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPF (10aa)
- FPNITNLCPFGE (12aa)
- FPNITNLCPFGE (12aa)
- FPNITNL (7aa)
- KGIYQTSNFRVQPTESIVRFPNITNLCPFGE (31aa)
- GEVFNATR (8aa)
- GEVFNATR (8aa)
- CPFGEVFNATR (11aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- GGVSVITPGTNTSNQVAVL (19aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- YQDVNCTEVPVAIHADQL (18aa)
- QDVNCTEVPVAIHADQL (17aa)
- LYQDVNCT (8aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- AGCLIGAEHVNNSYE (15aa)
- AGCLIGAEHVNNSYE (15aa)
- HVNNSYECDIPIGAGICASYQTQTNSPR (28aa)
- HVNNSYECDIPIGAGICASYQTQTNSPR (28aa)
- HVNNSYE (7aa)
- HVNNSYE (7aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- QIYKTPPIKDFGGFNFSQILPDPSKPSK (28aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNF (7aa)
- NFSQILPDPSK (11aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSK (16aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- KNFTTAPAICHDGK (14aa)
- KNFTTAPAICHDGK (14aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- CVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPRE (61aa)
- VPAQEKNF (8aa)
- VPAQEKNF (8aa)
- VPAQEKNF (8aa)
- AHFPREGVFVSNGTHWFVTQR (21aa)
- AHFPREGVFVSNGTHWFVTQR (21aa)
- NFTTAPAICHDGKAHFPR (18aa)
- NFTTAPAICHDGKAHFPR (18aa)
- NFTTAPAICHDGK (13aa)
- NFTTAPAICHDGK (13aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- HVTYVPAQEKNF (12aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- GVFVSNGTHWFVTQR (15aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- EGVFVSNGTHWF (12aa)
- VSNGTHW (7aa)
- VSNGTHWF (8aa)
- NGTHWFV (7aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NLNESLIDLQELGK (14aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- IDRLNEVAKNLNESLIDLQE (20aa)
- IDRLNEVAKNLNE (13aa)
- NLNESLIDLQE (11aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:2 HexNAc:3 / N-Linked (avg mass : 951.8851)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- IVNNATNVVIK (11aa)
- IVNNATNVVIK (11aa)
-
- Hex:2 HexNAc:2 dHex:2 / N-Linked (avg mass : 1040.9761)
- BTI-Tn-5B1-4 (CVCL_C190)
- COVID-19 (DOID:0080600)
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTK (33aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- SSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKR (34aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- FQFCNDPFLGVYYHKNNK (18aa)
- FQFCNDPFLGVYYHKNNK (18aa)
- VYSSANNCTFE (11aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- NGTITDAVDCALDPLSE (17aa)
- NGTITDAVDCALDPLSE (17aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- TFLLKYNENGTITDAVDCALDPLSETK (27aa)
- FPNITNLCPFGE (12aa)
- FPNITNLCPFGE (12aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- VQPTESIVRFPNITNLCPFGEVFNATR (27aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- SIVRFPNITNLCPFGE (16aa)
- VFNATR (6aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- AGCLIGAEHVNNSYE (15aa)
- AGCLIGAEHVNNSYE (15aa)
- HVNNSYE (7aa)
- HVNNSYE (7aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- QIYKTPPIKDFGGFNFSQILPDPSKPSK (28aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNFSQILPDPSK (16aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- KNFTTAPAICHDGK (14aa)
- KNFTTAPAICHDGK (14aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- KNFTTAPAICHDGKAHFPRE (20aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GVFVSNGTHWFVTQR (15aa)
- GVFVSNGTHWFVTQR (15aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQK (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- YFKNHTSPDVDLGDISGINASVVNIQK (27aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NLNESLIDLQELGK (14aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- IDRLNEVAKNLNESLIDLQE (20aa)
- NLNESLIDLQELGKYEQYIK (20aa)
- NLNESLIDLQELGKYEQYIK (20aa)
- VAKNLNESLIDLQE (14aa)
-
- Hex:3 HexNAc:2 dHex:1 / N-Linked (avg mass : 1056.9755)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Site-specific glycan analysis of the SARS-CoV-2 spike (2020 - Yasunori Watanabe, Joel D. Allen, Daniel Wrapp, Jason S. McLellan, Max Crispin) / Status : Unreviewed
- Recombinant Spike glycoprotein (BTI-Tn-5B1-4) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- Recombinant Spike glycoprotein (FreeStyle 293-F) / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- QCVNLTTR (8aa)
- FSNVTWF (7aa)
- FSNVTWF (7aa)
- FSNVTWF (7aa)
- FSNVTW (6aa)
- SNVTWF (6aa)
- HAIHVSGTNGTKRF (14aa)
- HAIHVSGTNGTKRF (14aa)
- FHAIHVSGTNGTK (13aa)
- HAIHVSGTNGTK (12aa)
- FHAIHVSGTNGTKR (14aa)
- HAIHVSGTNGTKR (13aa)
- LIVNNATNVVIK (12aa)
- LIVNNATNVVIK (12aa)
- IVNNATNVVIK (11aa)
- IVNNATNVVIK (11aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- TQSLLIVNNATNVVIK (16aa)
- FQFCNDPFLGVYYHKNNKSWMESE (24aa)
- FQFCNDPFLGVYYHKNNKSWME (22aa)
- VYSSANNCTFEY (12aa)
- VYSSANNCTFE (11aa)
- VYSSANNCTFE (11aa)
- SEFRVYSSANNCTFE (15aa)
- SSANNCTF (8aa)
- SSANNCTF (8aa)
- VYSSANNCTF (10aa)
- SSANNCTFEY (10aa)
- SSANNCTFEY (10aa)
- VDLPIGINITR (11aa)
- PLVDLPIGINITR (13aa)
- PLVDLPIGINITR (13aa)
- NGTITDAVDCALDPLSE (17aa)
- NGTITDAVDCALDPLSE (17aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- TFLLKYNENGTITDAVDCALDPLSETK (27aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPFGEVFNATR (18aa)
- FPNITNLCPF (10aa)
- SIVRFPNITNLCPFGE (16aa)
- FPNITNLCPFGE (12aa)
- FPNITNLCPFGE (12aa)
- FPNITNL (7aa)
- RFPNIT (6aa)
- VFNATR (6aa)
- GEVFNATR (8aa)
- GEVFNATR (8aa)
- GEVFNATRF (9aa)
- GEVFNATRF (9aa)
- GEVFNATRF (9aa)
- CPFGEVFNATR (11aa)
- GGVSVITPGTNTSNQVAVLY (20aa)
- GGVSVITPGTNTSNQVAVLY (20aa)
- QDVNCTEVPVAIHADQLTPTWR (22aa)
- YQDVNCTEVPVAIHADQL (18aa)
- QDVNCTEVPVAIHADQL (17aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRR (37aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRAR (39aa)
- AGCLIGAEHVNNSYE (15aa)
- AGCLIGAEHVNNSYE (15aa)
- HVNNSYECDIPIGAGICASYQTQTNSPR (28aa)
- HVNNSYECDIPIGAGICASYQTQTNSPR (28aa)
- AGCLIGAEHVNNSY (14aa)
- HVNNSYE (7aa)
- HVNNSYE (7aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- NSVAYSNNSIAIPTNFTISVTTE (23aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- TPPIKDFGGFNFSQILPDPSKPSKR (25aa)
- QIYKTPPIKDFGGFNFSQILPDPSKPSK (28aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNFSQILPDPSKPSK (19aa)
- DFGGFNF (7aa)
- NFSQILPDPSK (11aa)
- VFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIE (39aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSKPSKR (20aa)
- DFGGFNFSQILPDPSK (16aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- TPPIKDFGGFNFSQILPDPSKPSK (24aa)
- KNFTTAPAICHDGK (14aa)
- KNFTTAPAICHDGK (14aa)
- VDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (47aa)
- VPAQEKNF (8aa)
- VPAQEKNF (8aa)
- VPAQEKNF (8aa)
- KNFTTAPAICHDGKAHFPRE (20aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- VPAQEKNFTTAPAICHDGK (19aa)
- NFTTAPAICHDGK (13aa)
- NFTTAPAICHDGK (13aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK (41aa)
- HVTYVPAQEKNF (12aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQR (16aa)
- GYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPR (46aa)
- GVFVSNGTHWFVTQR (15aa)
- GVFVSNGTHWFVTQR (15aa)
- EGVFVSNGTHW (11aa)
- EGVFVSNGTHWF (12aa)
- EGVFVSNGTHWF (12aa)
- VSNGTHW (7aa)
- VSNGTHWF (8aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- ELDKYFKNHTSPDVDLGDISGINASVVNIQKE (32aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- NHTSPDVDLGDISGINASVVNIQKE (25aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- EELDKYFKNHTSPDVDLGDISGINASVVNIQKE (33aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NHTSPDVDLGDISGINASVVNIQK (24aa)
- NLNESLIDLQELGK (14aa)
- NLNESLIDLQELGK (14aa)
- VAKNLNE (7aa)
- IDRLNEVAKNLNESLIDLQE (20aa)
- IDRLNEVAKNLNE (13aa)
- NLNESLIDLQELGKYEQYIK (20aa)
- NLNESLIDLQELGKYEQYIK (20aa)
- NLNESLIDLQE (11aa)
- VAKNLNESLIDLQE (14aa)
- EIDRLNEVAKNLNESLIDLQELGK (24aa)
-
- Hex:4 HexNAc:2 / N-Linked (avg mass : 1072.9749)
- COVID-19 (DOID:0080600)
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics (2020 - Dapeng Zhou, Xiaoxu Tian, Ruibing Qi, Chao Peng, Wen Zhang) / Status : Reviewed
- Site-specific glycan analysis of the SARS-CoV-2 spike (2020 - Yasunori Watanabe, Joel D. Allen, Daniel Wrapp, Jason S. McLellan, Max Crispin) / Status : Unreviewed
Suggested structure
Disease
Reference
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reference
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide
Source
Suggested structure
Disease
Reported glycosite
Mass spectrometry observed peptide